A new research has revealed why a protein that suppresses tumors also causes metastasis.
Scottish author Robert Louis Stevenson tapped into primal fears when he penned "Dr. Jekyll and Mr. Hyde," a 19th century novel about a sinister physician, raising the question, "Can evil and good exist in the same person?"
Changes in Environmental Policy to Prevent Cancer, an Effort by HEAL
Health and Environment Alliance focuses on policy changes at the EU level and the primary prevention focuses on changes through environmental policy.
Advertisement
As it turns out, cancer researchers are discovering that "good vs. bad" can also exist in the world of molecular genetics and one example is a protein, transforming growth factor beta (TGF-Beta) that suppresses tumor progression in pre-malignant cells, can also lead to the spread of cancer.
It has been a long-time puzzle how and when TGF-Beta switches its functional roles from a tumor suppressor to a metastasis promoter and now, scientists at The University of Texas believe they have an answer.
![New Target for Triple-Negative Breast Cancer Identified]( "New Target for Triple-Negative Breast Cancer Identified")
A new study by UT Southwestern Medical Center scientists has linked deficiency in a gene that controls autophagy, a process that recycles cell waste, with the triple-negative breast cancer.
The research demonstrates that another protein, known as 14-3-3 zeta, can switch TGF-Beta from suppressing tumors in pre-cancerous cells to promoting metastasis in breast cancer cells, spreading to the bones by changing the TGF-Beta's partner proteins.
Dihua Yu said that TGF-Beta has a dual role as both a tumor suppressor in normal and pre-malignant cells, and a metastasis promoter in late-stage cancer and the molecular mechanism by which TGF-Beta switches its role has long been an unsolved mystery for cancer researchers.
Yu added that TGF-Beta's known critical role in cancer has led to numerous efforts developing TGF-Beta inhibitors for anti-cancer therapeutics, but its penchant for both suppressing tumor progression while serving as a springboard for cancer metastasis has been a major obstacle in the development of anti-TGF-Beta therapies and they have developed a model that proposes that TGF-Beta's complicated nature may be governed by the cellular effects of SMAD's partner proteins.
Yu concluded that because TGF-Beta plays important roles in various physiological functions, it is crucial that we look at how to develop more specific drugs that selectively target TGF-Beta in cancer so as to discourage its ability to cause metastasis while maintaining its tumor suppression abilities in pre-cancerous cells.
The results are published in Cancer Cell.
Source: ANI
New Target for Triple-Negative Breast Cancer Identified
A new study by UT Southwestern Medical Center scientists has linked deficiency in a gene that controls autophagy, a process that recycles cell waste, with the triple-negative breast cancer.
Advertisement
The research demonstrates that another protein, known as 14-3-3 zeta, can switch TGF-Beta from suppressing tumors in pre-cancerous cells to promoting metastasis in breast cancer cells, spreading to the bones by changing the TGF-Beta's partner proteins.
Dihua Yu said that TGF-Beta has a dual role as both a tumor suppressor in normal and pre-malignant cells, and a metastasis promoter in late-stage cancer and the molecular mechanism by which TGF-Beta switches its role has long been an unsolved mystery for cancer researchers.
Yu added that TGF-Beta's known critical role in cancer has led to numerous efforts developing TGF-Beta inhibitors for anti-cancer therapeutics, but its penchant for both suppressing tumor progression while serving as a springboard for cancer metastasis has been a major obstacle in the development of anti-TGF-Beta therapies and they have developed a model that proposes that TGF-Beta's complicated nature may be governed by the cellular effects of SMAD's partner proteins.
Yu concluded that because TGF-Beta plays important roles in various physiological functions, it is crucial that we look at how to develop more specific drugs that selectively target TGF-Beta in cancer so as to discourage its ability to cause metastasis while maintaining its tumor suppression abilities in pre-cancerous cells.
The results are published in Cancer Cell.
Source: ANI
India Fighting Cancer Better Than the US: Renowned Oncologist
The incidence of cancer in India was coming down while it was on the rise in the United States and Europe, says a renowned surgical oncologist.
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News
The new study uncovers the efficacy of fixed-duration combination treatment in patients with high-risk leukemia.
The approvals of pipeline drugs such as momelotinib and Vonjo for myelofibrosis (a rare type of blood cancer) over some time will handle the critical unmet needs.
New study highlights the dual role that blood vessels can play in cancer immunotherapy and eliciting anti-tumor immune responses or even preventing breast cancer spread.
New study evaluated the association between exposure to the chemical agent orange and the development of blood cancer with increased bleeding and blood clot formation.
Study suggests two-year immunotherapy treatment for advanced lung cancer may be reasonable